| Yang Liu,Zhenyu You,Xiaohui Su,Bona Liu,Xuefei Liu. The cardiotoxicity and long-term efficacy of different doses of epirubicin in the adjuvant treatment of breast cancer patients: A case control study. Oncol Transl Med, 2014, 13: 410-412. |
| The cardiotoxicity and long-term efficacy of different doses of epirubicin in the adjuvant treatment of breast cancer patients: A case control study |
| Received:June 30, 2014 Revised:August 26, 2014 |
| View Full Text View/Add Comment Download reader |
| KeyWord:epirubicin; breast cancer; adjuvant chemotherapy; cardiotoxicity; long-term efficacy |
| Author Name | Affiliation | E-mail | | Yang Liu | Department of Oncology, 202 Hospital of the PLA, Shenyang 110003, China | doctor_yangliu@163.com | | Zhenyu You | Department of Oncology, 202 Hospital of the PLA, Shenyang 110003, China | | | Xiaohui Su | Department of Gastric Surgery, Cancer Hospital of Liaoning Province, Shenyang 110042, China | | | Bona Liu | Department of Oncology, 202 Hospital of the PLA, Shenyang 110003, China | | | Xuefei Liu | Department of Oncology, 202 Hospital of the PLA, Shenyang 110003, China | |
|
| Hits: 7300 |
| Download times: 1365 |
| Abstract: |
| Objective: The aim of the study was to observe the cardiac toxicity caused by different doses of epirubicin in the adjuvant treatment of breast cancer and to evaluate the long-term efficacy. Methods: The 180 cases of breast cancer patients received epirubicin based adjuvant chemotherapy. The patients were randomly assigned to high-dosage group (90 mg/m2), medium-dosage group (70 mg/m2) and low-dosage group (50 mg/m2), the primary endpoint was cardiac toxicity. The secondary outcomes were the 5-year overall survival (OS) and 5-year disease-free survival (DFS). Results: During chemotherapy, the clinical symptoms such as palpitation, dyspnea and paroxysmal nocturnal dyspnea occurred in 6 patients with the high-dosage group, 4 patients with the medium-dosage group and 3 patients with the low-dosage group. The number of patients who had changed in electrocardiogram (ECG) was 7, 5 and 4 in three groups, respectively. The echocardiographic showed each group had only one case with LVEF < 50%, there was no significantly difference (P > 0.05). In the three groups, the 5-year DFS rates were 73.3% (44/60) in high-dose group, 53.3% (32/60) in medium-dose group and 41.6% (25/60) in low dose group. The 5-year OS rates were 85.0% (51/60), 68.3% (41/60) and 58.3% (35/60) in three groups, respectively. The differences were statistically significant (P < 0.05). Conclusion: The high-dose epirubicin in adjuvant chemotherapy with CEF (cyclophosphamide, epirubicin and fluorouracil) regimen could improve the 5-year OS rate and 5-year DFS rate on patients of breast cancer. The cardiotoxicity was mild-moderate and well tolerated. |
| Close |
|
|
|